Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H23F3O5S.C6H14N2O2.2H2O |
Molecular Weight | 626.683 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.NCCCC[C@H](N)C(O)=O.CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC=C(OCC(O)=O)C(C)=C2
InChI
InChIKey=WTKSWPYGZDCUNQ-JZXFCXSPSA-N
InChI=1S/C21H23F3O5S.C6H14N2O2.2H2O/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26;7-4-2-1-3-5(8)6(9)10;;/h4-10,17H,3,11-13H2,1-2H3,(H,25,26);5H,1-4,7-8H2,(H,9,10);2*1H2/t17-;5-;;/m10../s1
MBX-8025 (Seladelpar) is an agonist of peroxisome proliferator-activated receptor delta. MBX-8025 improves insulin sensitivity and reverses dyslipidemia and hepatic storage of lipotoxic lipids to improve nonalcoholic steatohepatitis pathology in atherogenic diet-fed obese diabetic mice. MBX-8025 improves lipoprotein subfractions associated with atherogenic dyslipidemia. CymaBay Therapeutics is developing MBX-8025 for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and nonalcoholic steatohepatitis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q03181|||Q9BUD4 Gene ID: 5467.0 Gene Symbol: PPARD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/29404484 |
2.0 nM [EC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02955602
Phase 2 study to evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of treatment
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
470715
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
||
|
FDA ORPHAN DRUG |
429214
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
||
|
FDA ORPHAN DRUG |
543416
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
N1429130KR
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
PRIMARY | |||
|
C174732
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
PRIMARY | |||
|
91758782
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
PRIMARY | |||
|
928821-40-3
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
PRIMARY | |||
|
300000025612
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
PRIMARY | |||
|
EF-46
Created by
admin on Sat Dec 16 10:16:14 GMT 2023 , Edited by admin on Sat Dec 16 10:16:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD